Salvage Radioembolization of Liver-dominant Metastases with a Resin-based Microsphere: Initial Outcomes

Journal of Vascular and Interventional Radiology

Volumn 19, Issue 10, 2008, Pages 1427-1433

  Stuart, Jourdan E ^a   Tan, Benjamin ^a,c   Myerson, Robert J ^a,c   Garcia Ramirez, Jose ^a,c   Goddu, Sreekrishna M ^a,c   Pilgram, Thomas K ^b   Brown, Daniel B ^b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSPHERE; RESIN; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CARCINOMA; DIGESTIVE SYSTEM ULCER; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MALE; PRIORITY JOURNAL; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACRYLIC RESINS; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COLONIC NEOPLASMS; DRUG CARRIERS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 52149097130     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2008.07.009     Document Type: Article

References (51)

1. Landis S.H., Murray T., Bolden S., and Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 49 (1999) 8-31
2. Viadana E., Bross I.D., and Pickren J.W. An autopsy study of some routes of dissemination of cancer of the breast. Br J Cancer 27 (1973) 336-340
3. Coldwell D.M., Kennedy A.S., and Nutting C.W. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 69 (2007) 800-804
4. Hagemeister Jr. F.B., Buzdar A.U., Luna M.A., and Blumenschein G.R. Causes of death in breast cancer: a clinicopathologic study. Cancer 46 (1980) 162-167
5. Zinser J.W., Hortobagyi G.N., Buzdar A.U., Smith T.L., and Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5 (1987) 773-782
6. Bangash A.K., Atassi B., Kaklamani V., et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 18 (2007) 621-628
7. Nagorney D.M., and Gigot J.F. Primary epithelial hepatic malignancies: etiology, epidemiology, and outcome after subtotal and total hepatic resection. Surg Oncol Clin N Am 5 (1996) 283-300
8. Lewandowski R.J., Thurston K.G., Goin J.E., et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by (18F)fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16 (2005) 1641-1651
9. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (1998) 1413-1418
10. Pitot H.C., Wender D.B., O'Connell M.J., et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15 (1997) 2910-2919
11. Rothenberg M.L., Cox J.V., DeVore R.F., et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85 (1999) 786-795
12. Rothenberg M.L., Eckardt J.R., Kuhn J.G., et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14 (1996) 1128-1135
13. Rougier P., Van Cutsem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 (1998) 1407-1412
14. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25 (2007) 1539-1544
15. Murthy R., Xiong H., Nunez R., et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. J Vasc Interv Radiol 16 (2005) 937-945
16. Fraschini G., Charnsangavej C., Carrasco C.H., Buzdar A.U., Jabboury K.W., and Hortobagyi G.N. Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver. Am J Clin Oncol 11 (1988) 34-38
17. Fumoleau P., Delgado F.M., Delozier T., et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11 (1993) 1245-1252
18. Giroux M.F., Baum R.A., and Soulen M.C. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 15 (2004) 289-291
19. Li X.P., Meng Z.Q., Guo W.J., and Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol 11 (2005) 3782-3787
20. Vogl T.J., Mack M.G., Balzer J.O., et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 229 (2003) 457-464
21. Kennedy A.S., Coldwell D., Nutting C., et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65 (2006) 412-425
22. Campbell A.M., Bailey I.H., and Burton M.A. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 45 (2000) 1023-1033
23. Murthy R., Nunez R., Szklaruk J., et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25 suppl (2005) S41-S55
24. Ho S., Lau W.Y., Leung T.W., et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 23 (1996) 947-952
25. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
26. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003) 176-181
27. Murthy R., Brown D.B., Salem R., et al. Gastrointestinal complications associated with hepatic arterial yttrium-90 microsphere therapy. J Vasc Interv Radiol 18 (2007) 553-561
28. Kennedy A.S., Nutting C., Coldwell D., Gaiser J., and Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60 (2004) 1552-1563
29. Fernandez F.G., Drebin J.A., Linehan D.C., Dehdashti F., Siegel B.A., and Strasberg S.M. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240 (2004) 438-447
30. Fong Y., Cohen A.M., Fortner J.G., et al. Liver resection for colorectal metastases. J Clin Oncol 15 (1997) 938-946
31. Scheele J., Stang R., Altendorf-Hofmann A., and Paul M. Resection of colorectal liver metastases. World J Surg 19 (1995) 59-71
32. Steele Jr. G., Bleday R., Mayer R.J., Lindblad A., Petrelli N., and Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 9 (1991) 1105-1112
33. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309-318
34. Braun A.H., Achterrath W., Wilke H., Vanhoefer U., Harstrick A., and Preusser P. New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 100 (2004) 1558-1577
35. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
36. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
37. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) supports use as a single agent in patients with advanced colorectal cancer. Cancer Biol Ther 6 (2007) 11
38. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
39. Van Cutsem E., Siena S., Humblet Y., et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19 (2008) 92-98
40. Goldhirsch A., Gelber R.D., and Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 6 (1988) 89-97
41. Kato I., Severson R.K., and Schwartz A.G. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer 92 (2001) 2211-2219
42. O'Reilly S.M., Richards M.A., and Rubens R.D. Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer 26 (1990) 574-577
43. Wyld L., Gutteridge E., Pinder S.E., et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 89 (2003) 284-290
44. Adam R., Aloia T., Krissat J., et al. Is liver resection justified for patients with hepatic metastases from breast cancer?. Ann Surg 244 (2006) 897-907
45. Vlastos G., Smith D.L., Singletary S.E., et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 11 (2004) 869-874
46. Keller A.M., Mennel R.G., Georgoulias V.A., et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin c plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22 (2004) 3893-3901
47. Martin M., Ruiz A., Munoz M., et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8 (2007) 219-225
48. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
49. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
50. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
51. Traina T.A., Rugo H.S., and Dickler M. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21 (2007) 303-319